Oral MS drug Cladribine rejected by European drug agency
Oral MS drug Cladribine rejected by European drug agency
European regulators rejected Merck KGaA’s multiple sclerosis pill cladribine, the second setback this week for the German drugmaker seeking to compete with Novartis AG for a share of a new market.
The European Medicines Agency found the medicine’s benefits don’t outweigh the risks, Darmstadt, Germany-based Merck said in a statement today. Merck is weighing an appeal and still believes cladribine has the potential to generate $1 billion in revenue a year, said Elmar Schnee, head of the company’s drug unit, in a telephone interview. The stock dropped the most in seven months.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
MS-UK - http://www.ms-uk.org/
Isn't mad that some countries say ok to what could be very dangerous drugs whilst others feel the risk is too high??
Well lets see what happens with the Russian MS patients and the Australian MS patients who take it. I hope it works well and that the cancer risk is minimal. ( I have a feeling though that the cancer risk is probably very high)
Well lets see what happens with the Russian MS patients and the Australian MS patients who take it. I hope it works well and that the cancer risk is minimal. ( I have a feeling though that the cancer risk is probably very high)
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 557 Views
-
Last post by NHE
-
- 0 Replies
- 1683 Views
-
Last post by NHE
-
- 1 Replies
- 3185 Views
-
Last post by Tif
-
- 0 Replies
- 167 Views
-
Last post by DIM
-
- 2 Replies
- 1112 Views
-
Last post by DIM
-
- 1 Replies
- 2016 Views
-
Last post by raceya
-
- 1 Replies
- 1147 Views
-
Last post by Petr75
-
- 0 Replies
- 168 Views
-
Last post by NHE